Nissay Asset Management Corp Japan ADV Has $2.83 Million Position in IDEXX Laboratories, Inc. (IDXX)

Nissay Asset Management Corp Japan ADV Has $2.83 Million Position in IDEXX Laboratories, Inc. (IDXX)

Nissay Asset Management Corp Japan ADV trimmed its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 12,636 shares of the company’s stock after selling 892 shares during the quarter. Nissay Asset Management Corp Japan ADV’s holdings in IDEXX Laboratories were worth $2,825,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Pearl River Capital LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $28,000. Osborn Williams & Donohoe LLC purchased a new position in IDEXX Laboratories during the first quarter worth about $90,000. Sontag Advisory LLC purchased a new position in IDEXX Laboratories during the fourth quarter worth about $79,000. Quantamental Technologies LLC purchased a new position in IDEXX Laboratories during the fourth quarter worth about $92,000. Finally, Hall Laurie J Trustee grew its position in IDEXX Laboratories by 25.0% during the first quarter. Hall Laurie J Trustee now owns 500 shares of the company’s stock worth $112,000 after buying an additional 100 shares in the last quarter. Institutional investors own 87.46% of the company’s stock.

In other news, Director Rebecca M. Henderson sold 8,790 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $241.57, for a total value of $2,123,400.30. Following the completion of the transaction, the director now directly owns 27,486 shares in the company, valued at approximately $6,639,793.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jacqueline Studer sold 11,600 shares of the company’s stock in a transaction dated Friday, February 15th. The stock was sold at an average price of $208.46, for a total value of $2,418,136.00. Following the completion of the transaction, the vice president now owns 8,648 shares of the company’s stock, valued at $1,802,762.08. The disclosure for this sale can be found here. Insiders sold a total of 65,457 shares of company stock valued at $15,530,423 over the last quarter. Company insiders own 2.70% of the company’s stock.

IDEXX Laboratories stock opened at $246.18 on Thursday. IDEXX Laboratories, Inc. has a 52 week low of $176.11 and a 52 week high of $256.22. The company has a debt-to-equity ratio of 14.81, a current ratio of 1.01 and a quick ratio of 0.74. The stock has a market cap of $20.88 billion, a P/E ratio of 57.79 and a beta of 0.97.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Wednesday, May 1st. The company reported $1.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $0.13. IDEXX Laboratories had a return on equity of 354,783.84% and a net margin of 17.33%. The business had revenue of $576.06 million during the quarter, compared to analysts’ expectations of $575.04 million. During the same period in the previous year, the business earned $1.01 earnings per share. The firm’s revenue was up 7.1% on a year-over-year basis. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 4.82 earnings per share for the current fiscal year.

IDXX has been the subject of several recent analyst reports. BidaskClub upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, March 22nd. Canaccord Genuity reduced their target price on IDEXX Laboratories from $255.00 to $254.00 and set a “buy” rating for the company in a research report on Tuesday, March 26th. Finally, Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $236.00 target price for the company in a research report on Monday, February 4th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. IDEXX Laboratories has an average rating of “Buy” and an average target price of $253.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Further Reading: How are dividend achievers different from dividend aristocrats?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Related posts

Leave a Comment